FDA accepts Labopharm's response for tramadol

TORONTO, Jan 16 (Reuters) - Labopharm Inc. (DDS.TO) said on Tuesday it has satisfied all the concerns raised by the U.S. Food and Drug Administration for the once-daily formulation of its pain medication, tramadol.

The company said the action date assigned by the FDA under the Prescription Drug User Fee Act is June 19, 2007.

($1=$1.16 Canadian)